[Federal Register Volume 68, Number 161 (Wednesday, August 20, 2003)]
[Notices]
[Page 50155]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-21229]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Blood Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Blood Products Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on September 18, 2003, from 
8 a.m. to 6 p.m.
    Location: Gaithersburg Hilton Hotel, 620 Perry Pkwy., Gaithersburg, 
MD.
    Contact Person: Linda A. Smallwood, Center for Biologics Evaluation 
and Research (HFM-302), Food and Drug Administration, 1401 Rockville 
Pike, Rockville, MD 20852, 301-827-3514, or FDA Advisory Committee 
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC 
area), code 19516. Please call the Information Line for up-to-date 
information on this meeting.
    Agenda: On September 18, 2003, the following committee updates are 
tentatively scheduled: (1) Announcement of appointment of the new 
Director, Division of Hematology, Office of Blood Research and Review, 
Center for Biologics Evaluation and Research; (2) summary of Public 
Health Service Advisory Committee on Blood Safety and Availability; (3) 
summary of National Heart, Lung and Blood Institute workshop on 
pathogen reduction and blood component safety; (4) approval of human 
immune deficiency virus, type 1 (HIV-1) group ``O'' sensitive assays; 
(5) revised guidance on Severe Acute Respiratory Syndrome; (6) updated 
donor travel survey; and (7) labeling and storage: Blood and blood 
components (proposed regulation). In the morning, the committee will 
also hear informational presentations on: (1) An overview of 
counterterrorism exercise; and (2) the current status of West Nile 
Virus safety. In the afternoon, the committee will hear presentations, 
discuss and provide recommendations on the topic of supplemental 
testing for HIV-1 and hepatitis C virus.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by September 8, 
2003. Oral presentations from the public will be scheduled between 
approximately 10 a.m. and 10:15 a.m., 11:30 a.m. and 12:30 p.m., and 
4:15 p.m. and 4:45 p.m. on September 18, 2003. Time allotted for each 
presentation may be limited. Those desiring to make formal oral 
presentations should notify the contact person before September 8, 
2003, and submit a brief statement of the general nature of the 
evidence or arguments they wish to present, the names and addresses of 
proposed participants, and an indication of the approximate time 
requested to make their presentation.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Linda A. Smallwood 
or Pearline K. Muckelvene at 301-827-1281 at least 7 days in advance of 
the meeting.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: August 13, 2003.
Peter J. Pitts,
Associate Commissioner for External Relations.
[FR Doc. 03-21229 Filed 8-19-03; 8:45 am]
BILLING CODE 4160-01-S